

**This item is the archived peer-reviewed author-version of:**

Xpert ultra can unambiguously identify specific rifampin resistance-conferring mutations

**Reference:**

Ng Kamela C. S., van Deun Armand, Meehan Conor J., Torrea Gabriela, Driesen Michele, Gabriels Siemon, Rigouts Leen, Andre Emmanuel, de Jong Bouke C.- Xpert ultra can unambiguously identify specific rifampin resistance-conferring mutations

Journal of clinical microbiology - ISSN 0095-1137 - Washington, Amer soc microbiology, 56:9(2018), UNSP e00686-18

Full text (Publisher's DOI): <https://doi.org/10.1128/JCM.00686-18>

To cite this reference: <https://hdl.handle.net/10067/1536910151162165141>

1 Xpert Ultra can unambiguously identify specific rifampicin resistance-conferring  
2 mutations

3

4 Kamela C. S. Ng,<sup>a#</sup> Armand van Deun,<sup>a,b</sup> Conor J. Meehan,<sup>a</sup> Gabriela Torrea,<sup>a</sup> Michèle

5 Driesen,<sup>a</sup> Siemon Gabriëls,<sup>a</sup> Leen Rigouts,<sup>a,c</sup> Emmanuel André,<sup>d\*</sup> Bouke C. de Jong<sup>a\*</sup>

6

7 Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical

8 Medicine, Antwerp, Belgium<sup>a</sup>; International Union Against Tuberculosis and Lung

9 Disease, Paris, France<sup>b</sup>; Department of Biomedical Sciences, University of Antwerp,

10 Antwerp, Belgium<sup>c</sup>; Laboratory of Clinical Bacteriology and Mycology, KU Leuven,

11 Leuven, Belgium<sup>d</sup>

12

13 Running Head: Discriminatory Xpert Ultra data

14

15 \* contributed equally

16

17 #Address correspondence to Kamela C. S. Ng, kng@itg.be.

18 Postal address: Mycobacteriology Unit, Biomedical Sciences Department, Institute of

19 Tropical Medicine, 155 Nationalestraat, 2000 Antwerpen, Belgium

20 Email address: kng@itg.be

21 Phone: +32(0)33455345

22 Fax number: +32(0)32476333

23

24

25 Introduction

26 The deluge of data produced by XpertMTB/RIF (Cepheid) can help improve global  
27 rifampicin-resistant tuberculosis (RR-TB) control strategies through molecular  
28 epidemiological surveillance (1, 2). Recently, a new version of the test – Xpert Ultra  
29 (hereinafter called Ultra) was released (3). Determining the relationship between RR-  
30 conferring *rpoB* mutations, Ultra probes, and melting temperature shifts ( $\Delta T_m$ ) – the  
31 difference between mutant and wildtype melting temperatures – allows Ultra results to  
32 be utilized for rapid detection of RR-TB strains and related underlying *rpoB* mutations.

33 Methods

34 To determine the reliability of Ultra results for predicting specific mutations, we tested 10  
35 rifampicin susceptible (RS)-TB, and 107 RR-TB strains harboring 36 unique RR-  
36 conferring mutations, from the Belgian Coordinated Collections of Microorganisms in the  
37 Institute of Tropical Medicine Antwerp, following a protocol previously described (2)  
38 (Supplemental file 1). We then compared Ultra raw results with available *rpoB*  
39 sequences of the strains.

40 Results

41 Overall, 29/30 (97%) mutations inside the Rifampicin Resistance Determining Region  
42 (RRDR) were correctly identified by Ultra. Of concern, mutation His445Arg gave a “RIF  
43 Resistance INDERTERMINATE” result among 3/4 strains tested while it was reported as  
44 RR in the initial validation study (3). The silent mutation Thr444Thr was not reported as  
45 RR (Figure 1). The RR-conferring mutations on codons 170, 250, 299, 482, and 491  
46 situated outside the RRDR were not detected.

47 The probe reactions observed were largely in agreement with previous results (3) albeit  
48 we noted that mutations Met434Val, Met434Thr and those in codon 435 were captured

49 only by probe rpoB2; Ser450Leu and Ser450Trp were captured by both probes rpoB3  
50 and rpoB4a, His445Arg was captured only by probe rpoB3; and Lys446Gln was  
51 captured only by probe rpoB4.

52 All mutations except those in codon 450 were associated with a negative  $\Delta T_m$  (Figure  
53 2). The combination of  $\Delta T_m$  values with the capturing probes enabled to differentiate  
54 mutations in codons 428, 430, 431, 432, 434, 435, 441, 445, 446, and 452, including  
55 disputed mutations (4) (Table 1). Mutation Asp435Tyr was unambiguously distinguished  
56 from Asp435Val through probe rpoB2 $|\Delta T_m|$ , while mutations Ser441Gln and Ser441Leu  
57 were discriminated from the rest by  $|\Delta T_m|$  values of probes rpoB2 and rpoB3. Mutations  
58 His445Asp and His445Tyr were distinguished from disputed mutations His445Leu and  
59 His445Asn through probe rpoB3  $|\Delta T_m|$ . Ser450Leu was distinguished from Ser450Trp  
60 by probe rpoB4A  $|\Delta T_m|$ . The indeterminate result associated with His445Arg may be  
61 caused by its  $|\Delta T_m|=1.8^\circ\text{C}$  compared with  $|\Delta T_m|$  typically exceeding  $2^\circ\text{C}$  for other  
62 mutations. Our recent experience with Ultra on diagnostic sputum samples only  
63 pertained to the Ser450Leu and His445Asp mutations, for which the  $\Delta T_m$  corresponded  
64 exactly with the  $\Delta T_m$  we observed on bacterial thermolysates. This should be validated  
65 more extensively, which is beyond the scope of our present study.

## 66 Conclusions

67 Our findings confirm the ability of Ultra to unambiguously identify a wide range of RRDR  
68 mutations. With the unprecedented roll-out of XpertMTB/RIF and associated connectivity  
69 solutions, such as DataToCare (Savics, Belgium) and GXAlert (SystemOne, USA) (2),  
70 Ultra results may allow to rule-out transmission between RR-TB patients in a specific  
71 setting (Figure S1), distinguish relapse from reinfection (5) (Figure S2), and resolve  
72 discordance between an RR Ultra result and a low-level RS phenotypic result due to a

73    disputed mutation. For such applications, it is key that  $\Delta T_m$  values are included in the  
74    exported results.  
75    Acknowledgement  
76    This work was supported by Erasmus Mundus Joint Doctorate Fellowship grant 2016-  
77    1346 to KCSN.

## 78 References

- 79 1. Andre E, Isaacs C, Affolabi D, Alagna R, Brockmann D, de Jong BC, Cambau E,  
80 Churchyard G, Cohen T, Delmee M, Delvenne JC, Farhat M, Habib A, Holme P,  
81 Keshavjee S, Khan A, Lightfoot P, Moore D, Moreno Y, Mundade Y, Pai M, Patel  
82 S, Nyaruhirira AU, Rocha LE, Takle J, Trebucq A, Creswell J, Boehme C. 2016.  
83 Connectivity of diagnostic technologies: improving surveillance and accelerating  
84 tuberculosis elimination. *Int J Tuberc Lung Dis* 20:999-1003.
- 85 2. Ng KC, Meehan CJ, Torrea G, Goeminne L, Diels M, Rigouts L, de Jong BC,  
86 Andre E. 2018. Potential Application of Digitally Linked Tuberculosis Diagnostics  
87 for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission:  
88 Validation and Analysis of Test Results. *JMIR Med Inform* 6:e12.
- 89 3. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP,  
90 Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta  
91 P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A,  
92 Denkinge CM, Persing D, Kwiatkowski R, Jones M, Alland D. 2017. The New  
93 Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and  
94 Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. *MBio* 8.
- 95 4. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L,  
96 Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for  
97 tuberculosis: challenging the gold standard. *J Clin Microbiol* 51:2633-40.
- 98 5. Rosser A, Marx FM, Pareek M. 2018. Recurrent tuberculosis in the pre-  
99 elimination era. *Int J Tuberc Lung Dis* 22:139-150.

100

101 Figure 1. Overview of Xpert Ultra test results. The observed probe reactions for each  
102 RRDR mutation were overlaid on claimed probe coverage (light gray). Shown in black  
103 are probe reactions concordant with manufacturer claims; in blue are probe reactions  
104 missed by one probe but captured by another probe; and in red is a probe reaction  
105 representing “RIF Resistance INDETERMINATE” result from 3 out of 4 strains tested.  
106 Results in striped pattern were superimposed for greater visibility.

107

108 Figure 2. Melting temperature shift ( $\Delta T_m$ ) observed upon detection of a rifampicin  
109 resistance (RR)-conferring *rpoB* mutation in the rifampicin resistance determining region  
110 (RRDR) by Xpert Ultra. The y-axis reflects the melting temperature difference between  
111 mutant and wildtype probe-amplicon hybrids ( $\Delta T_m$ ), while the x-axis shows the  
112 mutations we tested. The data points on the graph are  $\Delta T_m$  values grouped by  
113 associated Ultra probe (differentiated by color) corresponding with a specific *rpoB*  
114 mutation. X-axis labels in brown are disputed mutations.

Table 1. Xpert Ultra raw results – capturing probe, wildtype melt peak temperature ( $T_m$ ) range and mean, mutant (mut)  $T_m$  range, and absolute value of melting temperature shift ( $\Delta T_m$ , range for multiple strains tested) – associated with rifampicin resistance-conferring mutations and corresponding nucleotide changes as determined by *rpoB* sequencing. Unique combinations of Ultra probe and  $\Delta T_m$  unambiguously differentiate most but not all mutations within the Rifampicin Resistance Determining Region (RRDR), including disputed ones in italics.



Mutation	Number of strains tested	Nucleotide change	Xpert Ultra Probe	wildtypeTm range   mean	mutTm range	$\Delta$ Tm range
Val170Phe	3	gtc > Ttc	ND	ND	ND	ND
Glu250Gly	2	gag > gGg	ND	ND	ND	ND
Arg299Cys	1	cgc > Tgc	ND	ND	ND	ND
Ser428Arg	1	agc > agG	rpoB1		65.8	3.5
* <i>Leu430Pro</i>	8	ctg > cCg	rpoB1	69.1-69.5   69.3	63.0-63.4	5.9 - 6.3
*Ser431Gly	1	agc > Ggc	rpoB1		66.4	2.9
*Gln432Glu	1	caa > Gaa	rpoB1		65.9	3.4
*Met434Ile	1	atg > atA	rpoB2		69.8	3.2
*Met434Val	1	atg > Gtg	rpoB2		70.5	2.5
Me434Thr	1	atg > aCg	rpoB2		69.7	3.3
Asp435 Gly	1	gac > gGc	rpoB2	72.8-73.2   73	69.7	3.3
*Asp435Glu	1	gac > gaA	rpoB2		70.2	2.8
*Asp435Phe	1	gac > TTc	rpoB2		67.7	5.3
* <i>Asp435Tyr</i>	11	gac > Tac	rpoB2		68.6-68.9	4.0-4.4
*Asp435Val	5	gac > gTc	rpoB2		69.3-69.5	3.5-3.7
*Ser441Gln	1	tcg > CAg	rpoB2; rpoB3	72.8-73.2; 73; 75.5-76.0; 75.75	68.3; 73.5	4.7; 2.3
*Ser441Leu	1	tcg > tTg	rpoB2; rpoB3		70.0; 73.5	3; 2.3

Thr444Thr	1	acc > acG	ND	ND	ND	ND
*His445Gln	1	cac > caG	rpoB3		72.2	3.6
*His445Gln	1	cac > caA	rpoB3		71.7	4.1
His445Gly	1	cac > GGc	rpoB3		70.9	4.9
His445Thr	1	cac > ACc	rpoB3		70.9	4.9
*His445Ser	1	cac > AGc	rpoB3		71.1	4.7
*His445Asp	3	cac > Gac	rpoB3	75.5-76.0   75.75	71.9-72.1	3.7-3.9
*His445Leu	2	cac > cTc	rpoB3		72.2-72.3	3.5-3.6
*His445Asn	2	cac > Aac	rpoB3		72.3-72.4	3.4-3.5
*His445Tyr	4	cac > Tac	rpoB3		72.5-72.6	3.2-3.3
*His445Arg	4	cac > cGc	rpoB3		73.9	1.9
*Lys446Gln	1	aag > Cag	rpoB4B	67.0-67.6   67.3	62.3	5.0
*Ser450Phe	1	tcg > tTC	rpoB3	75.5-76.0   75.75	71.8	4.0
*Ser450Leu	14	tcg > tTg	rpoB3; rpoB4A	75.5-76.0   75.75; 67.0-67.6   67.3	72.9-73.3; 73.3- 73.8	2.5-2.9; 3.6-6.5
*Ser450Trp	3	tcg > tGg	rpoB3; rpoB4A		73.1-73.5; 70.6- 71.0	2.3-2.7; 3.3-3.7
*Leu452Pro	12	ctg > cCg	rpoB4B	67.0-67.6   67.3	61.2-61.6	5.7-6.1
Thr482Asn	1	acc > aAc	ND	ND	ND	ND
Ile491Phe	10	atc > Ttc	ND	ND	ND	ND
Ile491Val	1	atc > Gtc	ND	ND	ND	ND

\* RRDR mutations distinguishable by unique combinations of Ultra probes and  $\Delta T_m$ ; ND - strains that harbor corresponding mutations outside the RRDR yielded 'RIF Resistance NOT DETECTED' result



